Ozempic Joint and Muscle Pain: What the Evidence Actually Shows

Joint pain and muscle aches are real complaints among people taking GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — but they are also widely misunderstood. In the major obesity trials, arthralgia (joint pain) and myalgia (muscle pain) were reported but uncommon, and the mechanism is usually indirect: not a chemical toxicity aimed at your joints, but the downstream effects of fast, large weight loss. Those effects include loss of lean (muscle) mass that leaves joints less supported, dehydration and electrolyte shifts that trigger muscle cramps, reduced food intake creating nutrient gaps, changes in activity that strain deconditioned muscles, and pre-existing osteoarthritis becoming more noticeable. Crucially, the long-term picture for the big weight-bearing joints — knees and hips — usually points the other way: losing weight reduces the load on those joints and tends to improve pain over time. This article explains what the trials actually show, the real mechanisms behind aches and cramps, what helps, and the red flags that warrant a clinician's evaluation. It is distinct from our muscle-loss articles: this is about pain, not mass.

Does Ozempic cause joint and muscle pain? What the trials show

Arthralgia and myalgia do appear on the adverse-event lists of the large GLP-1 obesity trials, but they are not among the common, dose-defining side effects the way nausea, vomiting, and diarrhea are. In STEP-1, semaglutide produced an average of about −14.9% body weight over 68 weeks, and the dominant adverse events were gastrointestinal (Wilding 2021^[1]). In SURMOUNT-1, tirzepatide produced up to roughly −21% body weight, again with gastrointestinal effects leading the safety profile (Jastreboff 2022^[2]). Musculoskeletal complaints such as joint or muscle pain were reported but uncommon, and frequently occurred at similar rates in placebo arms — a sign that much of it tracks with weight loss and aging rather than the drug itself.

Why it happens — the indirect mechanisms

1. Rapid weight loss and lean-mass loss leave joints less supported

Every method of weight loss — diet, surgery, or GLP-1 — takes some lean (muscle) tissue along with the fat. In the SURMOUNT-1 DXA body-composition substudy, roughly a quarter of total weight lost on tirzepatide was lean mass, with the same fat-to-lean split in the placebo arm, confirming the ratio reflects the physiology of weight loss rather than a drug-specific effect (Look 2025^[3]). Across all weight-loss modalities the lean-tissue fraction clusters around 20–30% and tilts higher when loss is faster (Cava 2017^[4]; Stefanakis 2024^[5]). Muscle is what stabilizes and offloads joints; when the muscles around the hips, knees, and shoulders lose volume and strength, those joints work harder and can ache, and deconditioned muscle is more prone to strain. This is why the single most useful intervention overlaps with muscle preservation — covered in depth in our GLP-1 muscle-loss prevention protocol and tirzepatide lean-mass deep-dive. Note the distinction: those articles are about losing muscle mass; this one is about the pain that can accompany the change.

2. Dehydration and electrolyte shifts drive muscle cramps

Muscle cramps — sudden, involuntary, painful contractions, classically in the calves or feet at night — are one of the most common muscle complaints people describe on a GLP-1, and the mechanism is usually fluid and electrolyte balance, not the drug. GLP-1 medications suppress appetite and thirst and frequently cause vomiting or diarrhea, all of which reduce fluid and electrolyte intake and increase losses. The exercise-associated muscle cramp literature implicates dehydration, electrolyte depletion (sodium, and clinically magnesium and potassium), and neuromuscular fatigue as contributors (Miller 2022^[6]). On a GLP-1, the practical drivers are simple: you are eating and drinking less, and any GI losses compound it. Staying well hydrated and not neglecting electrolytes is the first-line response.

3. Reduced food intake creates nutrient gaps

Because GLP-1 medications cut appetite sharply, total intake of protein, calories, and micronutrients can fall well below what supports muscle and connective tissue. Inadequate protein accelerates lean-mass loss in a deficit (Cava 2017^[4]), and low overall intake can leave shortfalls in electrolytes and micronutrients that contribute to cramps and aches. The fix is deliberate: prioritize protein and nutrient-dense food even when appetite is low, rather than letting intake drift down with hunger.

4. Changed activity and pre-existing osteoarthritis become more noticeable

Two activity-related effects show up. First, many people become more active as they lose weight — new or increased exercise loads muscles and joints that were deconditioned, producing ordinary delayed-onset soreness and, sometimes, overuse strain when ramped up too fast. Second, pre-existing osteoarthritis does not vanish overnight; as people move more and pay closer attention to their bodies, joints with underlying arthritis can become more noticeable before the longer-term benefit of reduced load sets in. Neither is a drug toxicity — both are predictable consequences of changing how a body moves and what it weighs.

The other side: weight loss usually improves weight-bearing joint pain

It would be incomplete — and inaccurate — to frame GLP-1 medications as simply “causing joint pain.” For the big weight-bearing joints, the dominant long-term effect of weight loss is the opposite. Each pound lost removes several pounds of peak load from the knee with every step, and the IDEA randomized trial showed that intensive weight loss in adults with knee osteoarthritis reduced knee-joint compressive loads, lowered inflammation, and improved pain and function (Messier 2013^[7]); the same cohort's long follow-up reinforced the durability of metabolic and clinical benefit (Welhaven 2024^[8]).

More directly relevant to this class of drug: the STEP 9 randomized trial tested semaglutide specifically in people with obesity and knee osteoarthritis and found that, alongside weight loss, it reduced knee osteoarthritis pain and improved physical function versus placebo (Bliddal 2024^[9]). Mechanistic reviews are now examining whether GLP-1 receptor agonists have additional anti-inflammatory effects on joints beyond weight loss alone, though that remains an open question (Ryan 2025^[10]). The takeaway: transient aches during rapid loss are common, but for arthritic knees and hips the trajectory over months usually points toward less pain, not more.

What helps — practical, evidence-based steps

Because the mechanisms are indirect, the most effective responses target the underlying drivers: muscle, hydration, and intake.

1. Resistance training, 2–3 sessions per week. This is the highest-evidence intervention for protecting the muscle that supports your joints. A meta-analysis of resistance training during caloric restriction found it largely abolished the lean-mass loss otherwise seen with dieting (Sardeli 2018^[11]), and resistance training preserves strength even in an energy deficit (Murphy 2022^[12]). Stronger muscles around a joint mean better support and less ache. Start gently if deconditioned and progress gradually.
2. Protein at roughly 1.2–1.6 g/kg per day (up to about 2.0 g/kg on a GLP-1). Adequate protein is what lets training translate into preserved muscle; higher-protein intake during an energy deficit reduces fat-free-mass loss and, with training, can even build lean mass (Longland 2016^[13]; Cava 2017^[4]). With appetite suppressed, eat protein first at each meal.
3. Hydration and electrolytes for cramps. Drink consistently through the day rather than relying on thirst (which the medication blunts), and do not neglect sodium, potassium, and magnesium from food or, if appropriate, supplementation — the levers most relevant to muscle cramps (Miller 2022^[6]). Cramps that are frequent or severe, or that come with weakness, warrant a check of electrolytes with your clinician.
4. Sensible activity progression. Increase exercise gradually to avoid overuse strain; expect ordinary post-exercise soreness from new movement, which is not a drug side effect. Low-impact options (cycling, swimming, walking) are gentle on arthritic joints while you build strength.
5. Slower titration where appropriate. Because faster loss takes proportionally more muscle, a more gradual dose escalation discussed with your prescriber can reduce the lean-mass share of weight lost and ease the musculoskeletal transition (Stefanakis 2024^[5]).

Red flags — when joint or muscle pain needs evaluation

Most aches and cramps on a GLP-1 are benign and respond to the steps above. Some patterns, however, deserve prompt medical attention rather than self-management:

• Severe, rapid-onset, or progressive muscle pain — especially with weakness, dark or cola-colored urine, or fever. This combination can signal serious muscle injury (rhabdomyolysis) or another myopathy and needs urgent evaluation, including bloodwork.
• Muscle pain in someone also taking a statin or other myotoxic drug, where a new or worsening pattern should be reviewed with a clinician.
• A single hot, swollen, intensely painful joint, which can indicate infection or acute gout rather than ordinary aches and warrants same-day assessment.
• Cramps that are frequent, severe, or accompanied by significant weakness — have electrolytes checked, since persistent low potassium, magnesium, or sodium needs correction.
• Joint pain that is steadily worsening rather than improving as weight stabilizes, or that limits daily function, which deserves a proper musculoskeletal evaluation rather than being attributed automatically to the medication.

As a general rule: ordinary, mild, activity-related aches and occasional cramps that respond to hydration, protein, and training are expected. Pain that is severe, rapidly worsening, paired with weakness or systemic symptoms, or that fails to settle is a reason to involve a clinician promptly.

How this differs from muscle-loss concerns

It is easy to conflate two different things. Muscle loss is the reduction in lean mass that accompanies any large weight loss — a body-composition issue you manage with protein and resistance training to protect strength and metabolism. Muscle and joint pain — the subject here — is a symptom that can arise from that loss, from cramps, from nutrient gaps, or from changed activity. They overlap (the same protein-and-training protocol helps both), but they are not the same complaint. For the body-composition and prevention details, see our muscle-loss prevention protocol and tirzepatide lean-mass evidence. For a broader run-through of common GLP-1 side-effect questions, see our GLP-1 side effects, answered guide.

Bottom line

• Joint pain (arthralgia) and muscle pain (myalgia) are reported on GLP-1 medications but were uncommon in the major obesity trials, where gastrointestinal effects dominate the safety profile (Wilding 2021^[1]; Jastreboff 2022^[2]).
• The pain is usually indirect, not direct drug toxicity: rapid weight loss with lean-mass loss leaving joints less supported (Look 2025^[3]), dehydration and electrolyte shifts driving cramps (Miller 2022^[6]), nutrient gaps from reduced intake, and changed activity unmasking pre-existing osteoarthritis.
• For weight-bearing joints, weight loss usually improves pain long-term — intensive weight loss reduced knee load and pain in the IDEA trial (Messier 2013^[7]), and semaglutide reduced knee osteoarthritis pain in STEP 9 (Bliddal 2024^[9]).
• What helps: resistance training 2–3x/week (Sardeli 2018^[11]), protein 1.2–1.6 g/kg, hydration plus electrolytes, sensible activity progression, and slower titration where appropriate.
• Red flags: severe or rapid muscle pain with weakness, dark urine, or fever; a single hot swollen joint; or pain that steadily worsens — get evaluated promptly.